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OBJECTIVE — Tocomparescreen-detecteddiabetesprevalenceandthedegreeofdiagnostic
agreement by ethnicity with the current oral glucose tolerance test (OGTT)-based and newly
proposed A1C-based diagnostic criteria.
RESEARCH DESIGN AND METHODS — Six studies (1999–2009) from Denmark,
the U.K., Australia, Greenland, Kenya, and India were tested for the probability of an A1C
6.5% among diabetic case subjects based on an OGTT. The difference in probability between
centers was analyzed by logistic regression adjusting for relevant confounders.
RESULTS — Diabetes prevalence was lower with the A1C-based diagnostic criteria in four of
six studies. The probability of an A1C 6.5% among OGTT-diagnosed case subjects ranged
widely (17.0–78.0%) by study center. Differences in diagnostic agreement between ethnic
subgroups in the U.K. study were of the same magnitude as between-country comparisons.
CONCLUSIONS — A shift to an A1C-based diagnosis for diabetes will have substantially
different consequences for diabetes prevalence across ethnic groups and populations.
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R
ecently, an international expert com-
mitteereportrecommendedashiftin
the diagnostic tool for diabetes from
the 75-g oral glucose tolerance test (OGTT)
to A1C (1), thereby proposing replacement
of the current World Health Organization
(WHO) criteria (2). More speciﬁcally, an
A1C threshold of 6.5% was recom-
mended,asthisvaluehasbeenshowntobe
strongly related to retinopathy (1). In their
report, the international expert committee
emphasizes that it is premature to establish
separate diagnostic thresholds based on
race/ethnicity and that the new diagnostic
criterion is likely to identify different indi-
viduals than those identiﬁed by the WHO
criteria (1). Previous studies have shown
A1Clevelsinindividualswithimpairedglu-
cose tolerance or diabetes to differ by race
and ethnicity (3–5). We aimed to compare
diabetes prevalence and the degree of diag-
nostic agreement between the OGTT- and
A1C-based deﬁnitions by race/ethnicity in
six different countries. Below, the term dia-
betesisreferringtodiabetesassessedbyone
OGTT or one A1C at screening.
RESEARCH DESIGN AND
METHODS— Six studies including
populations from different ethnic origins
were included in the analysis (6–11).
Populations from Denmark (Inter99
study), the U.K. (Whitehall II study,
phase7),Australia(TheAustralianDiabe-
tes, Obesity and Lifestyle Study [Aus-
Diab]), Greenland (Inuit Health in
Transition Study), Kenya, and India
(Chennai Urban Rural Epidemiology
Study [CURES]) were included.
Datawerecollectedduringtheperiod
1999–2009. Participants were excluded
if they had missing OGTT or A1C mea-
surements or known diabetes (self-
reported). In the Inter99 study, 5.6%
were not of Danish nationality and were
excludedfromtheanalyses.IntheWhite-
hall II study, whites were included in the
main analysis, whereas south Asian
(4.2%) and black (1.9%) participants
were analyzed in a subsidiary analysis. In
the AusDiab study, only individuals born
in Australia or New Zealand who spoke
English at home and were not of Aborig-
inal/Torres Strait Islander origin were in-
cluded (76.2%). In the Inuit Health in
Transition Study, only Inuit participants
were included in the analysis (95.5%).
The participants in the study from Kenya
were all black, and participants in the
CURES study were all of Indian origin. A
totalof23,094participantswereincluded
in this analysis.
Participants were categorized into
four groups based on their OGTT results
(diabetes or no diabetes) and A1C levels
(6.5% or 6.5%). Exact 95% CIs were
calculated for proportions (12). The
probability of an A1C 6.5% among di-
abetic case subjects based on an OGTT
was calculated. This probability is effec-
tivelythesensitivityofanA1Ccutpoint
of 6.5% with the WHO criteria as the
gold standard. The magnitude of the
difference in probability between cen-
ters was analyzed using logistic regres-
sion analysis adjusted for relevant
confounders (age, sex, BMI, waist cir-
cumference, and smoking). A1C assays
were aligned to the Diabetes Control
and Complications Trial assay at each
study center according to local labora-
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RESULTS— The prevalence of diabe-
tes was lower in four of six studies
(Whitehall II, AusDiab, Inuit Health in
Transition, and Kenya) with the A1C di-
agnostic criterion than with the OGTT
(Table1).Theprobabilityofapersonhav-
ing an A1C 6.5% given the presence of
diabetes according to the OGTT differed
by study center (range 17.0–78.0%).
Overall, the magnitude of this difference
between centers was independent of dif-
ferences in age and sex distributions.
Further adjustment for BMI, waist cir-
cumference, and smoking reduced the
magnitude of the difference between
some centers, but the overall difference
remained signiﬁcant (P  0.0001). Pair-
wisecomparisonsbetweencentersonthis
difference in probability were signiﬁcant.
Exceptions were the contrasts between
WhitehallIIandGreenland,andthecom-
parisons between Kenya on the one hand
and Inter99, Whitehall II, AusDiab, and
Greenland on the other. These results did
not change when adjusting for age, sex,
BMI, waist circumference, and smoking.
We also performed a subsidiary anal-
ysis on the south Asian (n  204) and
black (n  91) minority groups in the
Whitehall II study. The differences in
agreement between the two diagnostic
criteria for diabetes between these ethnic
subgroups within Whitehall matched
those observed between populations in
the main analysis (online appendix). Dis-
regarding differences in study size, the
overall prevalence of diabetes was 18%
lower with an A1C-based diagnostic test
fordiabetes.Thecorrespondingprobabil-
ity of A1C 6.5% among diabetic case
subjects based on an OGTT was 43.5%.
CONCLUSIONS — The diabetes pre-
valence was more likely to be lower than
higher when replacing the OGTT diag-
nostic criteria with A1C. The rate was
63% higher in the Inter99 study, while it
was 82% lower in the AusDiab study.
These differences are quite substantial
andmayinpartbeduetomethodological
differences.
There was also a signiﬁcant discrep-
ancy in the magnitude of the OGTT and
A1C diabetes diagnosis overlap between
study populations of different ethnic ori-
gins, even after adjusting for age, sex,
BMI, waist circumference, and smoking.
However, the differences between the
white populations of Inter99, Whitehall
II, and AusDiab were also signiﬁcant and
of the same magnitude, suggesting that
part of the discrepancy in overlap can be
ascribed to difference in study methodol-
ogysuchastheA1Cassaymethod.Onthe
other hand, the subsidiary analysis of the
south Asian and black minorities com-
pared with the white majority group of
Whitehall II indicates that discrepancies
are at least partly due to ethnic dif-
ferences.
The lack of a signiﬁcant difference in
the pairwise comparisons between the
Kenyan population and four of ﬁve other
studies does not rule out a true difference
in the probability of A1C 6.5% among
OGTT-diagnosed diabetic case subjects
but may be due to the limited number of
individuals in the Kenyan data.
Although we cannot dismiss the pos-
sibility that part of the observed diagnos-
ticinconsistencyisduetomethodological
differences between studies, we can con-
clude that the proposed shift to A1C as
the diagnostic tool for diabetes is likely to
have a substantially different impact on
diabetes prevalence in different popula-
tions, partly due to differences in race/
ethnicity. However, future analyses on
ethnic differences between studies using
the same methodology are needed.
Acknowledgments— The CURES ﬁeld stud-
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Table 1—Background characteristics and diabetes prevalence by OGTT and A1C diagnostic criteria in different ethnic groups
Denmark U.K. Australia Greenland Kenya India
Inter99
Whitehall II
(phase 7) AusDiab
Inuit Health in
Transition CURES
Study period 1999–2001 2002–2004 1999–2000 2005–2009 2005–2006 2001–2004
n 5,932 4,563 7,800 2,321 296 2,182
Age (years) 46.2  7.9 60.5  5.9 50.9  14.4 44.1  14.6 37.6  10.6 38.8  12.6
Male subjects (%) 49.7 (48.4–51.0) 73.9 (72.6–75.2) 44.4 (43.3–45.5) 43.4 (41.4–45.5) 44.6 (38.8–50.5) 46.0 (43.9–48.1)
BMI (kg/m
2) 26.2  4.5 26.5  4.2 26.9  4.9 26.4  5.1 22.1  4.6 23.0  4.0
Waist circumference
(cm) 86.5  13.2 93.2  12.0 90.6  13.8 91.9  13.3 79.9  12.2 83.0  11.4
Current smoker (%) 36.0 (34.8–37.2) 6.8 (6.1–7.6) 16.3 (15.5–17.2) 66.1 (64.1–68.0) 10.5 (7.3–14.6) 18.6 (17.0–20.3)
Fasting plasma
glucose (mmol/l) 5.5  0.8 5.3  0.7 5.4  0.7 5.7  0.8 4.5  0.9 5.1  1.7
2-h plasma
glucose (mmol/l) 6.2  2.1 6.5  2.0 6.2  2.2 5.9  2.4 5.6  1.7 7.0  3.5
A1C (%) 5.8  0.5 5.2  0.5 5.1  0.4 5.7  0.4 5.0  0.6 5.9  1.2
Diabetes by OGTT (%) 4.2 (3.7–4.8) 3.7 (3.2–4.3) 4.0 (3.6–4.4) 7.0 (6.0–8.1) 3.4 (1.6–6.1) 10.2 (9.0–11.6)
Diabetes by A1C (%) 6.7 (6.1–7.3) 1.0 (0.7–1.3) 0.7 (0.5–0.9) 3.9 (3.1–4.7) 1.4 (0.4–3.4) 12.9 (11.5–14.4)
A1C 6.5% given
diabetes by OGTT (%) 42.6 (36.4–49) 25.0 (18.7–32.3) 17.0 (13.0–21.7) 29.6 (22.7–37.3) 20.0 (2.5–55.6) 78.0 (72.0–83.3)
Diabetes by OGTT given
A1C 6.5% (%) 27.0 (22.7–31.7) 91.3 (79.2–97.6) 98.1 (90.1–100) 53.3 (42.5–63.9) 50.0 (6.8–93.2) 61.9 (56.0–67.6)
Data are means  SD and proportions (95% CI). Diabetes by OGTT: fasting plasma glucose 7.0 mmol/l or 2-h plasma glucose 11.1 mmol/l. Diabetes by A1C:
A1C 6.5%.
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